Molecular Diagnostics Market to Reach $31 Billion by 2035, Growing at 6.4% CAGR | Roche, Abbott Laboratories, QIAGEN, Illumina

The global molecular diagnostics market, valued at USD 17 billion in 2025, will expand to USD 18 billion in 2026 and reach USD 31 billion by 2035, advancing at a compound annual growth rate of 6.4% over the forecast period. This near-doubling of market value over a decade reflects accelerating demand for precise, rapid disease detection across infectious diseases, oncology, and genetic conditions, as health systems worldwide shift from reactive treatment toward early-stage, molecularly informed care. For investors, diagnostics companies, and healthcare strategists, this growth trajectory represents one of the most material commercial opportunities in the medical technology sector through 2035.

To explore the complete findings, request a free sample of the report at: https://www.rootsanalysis.com/reports/molecular-diagnostics-market/request-sample.html

MARKET OVERVIEW
Molecular diagnostics refers to a category of medical testing that detects specific genetic sequences, including DNA and RNA, in biological samples such as blood, urine, or tissue. These tests identify nucleotide polymorphisms, deletions, insertions, and genetic rearrangements that signal the presence or risk of a disease. As a subcategory of in vitro diagnostics, molecular testing underpins more than 70% of healthcare decisions, according to the World Health Organization, which currently tracks over 40,000 in vitro diagnostics products in commercial use globally.

The market's growth trajectory is anchored in three structural forces converging simultaneously: rising disease burden, technological progress in genomics, and a systemic reorientation of healthcare toward personalized medicine. Recent activity among leading companies and governments underscores this momentum. In March 2026, the Ontario government committed CAD 1.1 million through the Northern Ontario Heritage Fund Corporation to RNA Diagnostics in Sudbury, supporting its VeriDART cancer diagnostic technology. That same month, Insight Molecular Diagnostics completed a multi-site reproducibility study for its GraftAssureDx kidney transplant monitoring test across Tampa General Hospital, Mayo Clinic, and Baylor Scott & White Health, bringing it closer to commercial readiness.

In September 2025, Illumina announced collaborations with multiple global pharmaceutical companies to develop companion diagnostics for KRAS gene alterations using its TruSight Oncology comprehensive genomic profiling platform. These developments illustrate how quickly the field is moving from research-stage genomics into applied clinical tools, creating durable revenue streams for companies positioned across the technology stack.

KEY GROWTH DRIVERS
Rising Demand for Personalized Medicine. Advanced molecular diagnostic tools such as polymerase chain reaction (PCR) and next generation sequencing give clinicians the genetic and molecular data needed to tailor treatments at the individual level. As healthcare systems in high-income and emerging markets alike adopt precision medicine protocols, demand for these technologies will intensify. This shift is not marginal; it is reshaping procurement decisions at hospital networks and reference laboratories on every continent.

Increasing Prevalence of Infectious and Chronic Diseases. The infectious diseases segment holds more than 40% of the current molecular diagnostics market share, driven by sustained demand to diagnose respiratory infections including influenza, RSV, and pneumonia. Simultaneously, rising rates of chronic conditions such as neurological and cardiovascular disease are opening new diagnostic applications. The neurological diseases segment is forecast to grow at 6.9% CAGR through 2035, supported by improved understanding of the genetic basis of conditions like Alzheimer's and Parkinson's disease.

Expansion of Point-of-Care Testing. Point-of-care molecular diagnostics, though currently accounting for 15% of market share, is the fastest-growing test-type segment, with a projected CAGR of 9.1%. The ability to deliver accurate molecular results at or near the patient site, without sending samples to central laboratories, is highly attractive for emergency departments, rural clinics, and outbreak response programs. Technology miniaturization is bringing capabilities previously confined to large instruments into handheld formats.

Strategic Industry Partnerships and Commercialization Activity. Companies across the sector are actively expanding through collaboration. In June 2025, Tracer Biotechnologies entered a strategic agreement with QIAGEN to co-develop minimal residual disease assays for solid tumors on QIAGEN's QIAcuity digital PCR platform. These agreements are enabling oncologists to monitor cancer recurrence through minimally invasive liquid biopsy approaches, lowering costs while improving patient access. Such partnership activity is accelerating the commercial pipeline and expanding market reach.

Technological Advancement Across Diagnostic Modalities. Beyond PCR and sequencing, innovations in component-resolved allergy diagnosis, mass spectrometry, and microarray platforms are widening the clinical utility of molecular testing. Advances in molecular allergology have reduced misdiagnosis rates in pollen-food syndrome by 40%, by distinguishing primary sensitizations from cross-reactivity. These improvements in sensitivity and specificity are raising clinician confidence in molecular results and driving adoption across new therapeutic areas.

MARKET SEGMENTATION
The molecular diagnostics market segments across test type, offering type, sample type, technology, therapeutic area, and end user. By test type, laboratory testing commands the majority of the market at 85% share in 2026, given its established infrastructure and the high volume of complex diagnostic work performed in centralized settings. However, point-of-care testing is outpacing laboratory testing in growth rate, expanding at a 9.1% CAGR as decentralized diagnostics gain clinical acceptance.

By offering type, reagents hold the dominant position at 70% market share, a function of their consumable nature and continuous replenishment cycle. The instruments segment is projected to grow slightly faster at a 6.6% CAGR, driven by recurring equipment upgrades and the adoption of next generation platforms. By technology, PCR holds more than 40% of the market in 2026; next generation sequencing is the fastest-growing technology segment at 7.3% CAGR, owing to its capacity to provide whole-genome context and support companion diagnostics development. By sample type, blood, serum, and plasma account for approximately 80% of the market, while urine-based diagnostics are growing at 7.0% CAGR, reflecting rising interest in non-invasive testing for urological cancers and infectious diseases.

To request quote of this report, please visit:
https://www.rootsanalysis.com/reports/molecular-diagnostics-market/request-quote.html

REGIONAL INSIGHTS
North America holds approximately 40% of the global molecular diagnostics market in 2026, a position it is expected to maintain through 2035. This leadership reflects the region's dense concentration of research and development activity, well-funded hospital networks with established laboratory infrastructure, and sustained demand for personalized medicine and companion diagnostics. The United States in particular benefits from a mature reimbursement framework for molecular tests and a regulatory environment that has progressively supported the commercialization of novel diagnostics. North American companies account for 55% of all molecular diagnostic solution providers tracked globally.

Asia is the fastest-growing regional market, forecast to expand at a 6.5% CAGR through 2035. The drivers are structural: a rapidly aging population, government-led investment in healthcare infrastructure, increasing prevalence of both infectious and chronic diseases, and growing clinical adoption of advanced diagnostic technologies in China, India, Japan, South Korea, and Southeast Asia. Increased healthcare spending across the Asia-Pacific bloc, combined with rising patient awareness and a maturing companion diagnostics sector, gives this region outsized long-term growth potential. Europe, meanwhile, remains a significant market anchored by strong public health systems in Germany, France, the United Kingdom, and Benelux countries, with regulatory harmonization under the EU's In Vitro Diagnostic Regulation framework shaping procurement and commercialization timelines.

COMPETITIVE LANDSCAPE
The molecular diagnostics market features more than 100 active companies spanning large multinationals, specialized mid-sized firms, and innovative smaller players. Key participants identified in the Roots Analysis report include Roche, Abbott Laboratories, QIAGEN, Illumina, Thermo Fisher Scientific, bioMerieux, Becton Dickinson, Hologic, Danaher, Siemens Healthineers, Bio-Rad, Agilent Technologies, QuidelOrtho, Sysmex, Revvity, BGI Genomics, DiaSorin, Grifols, Sansure, and Seegene, among others.

Roche holds the broadest portfolio and is widely recognized as the global market leader, with deep capabilities across PCR, sequencing, and companion diagnostics. The competitive battleground is increasingly defined by three factors: the ability to offer integrated platforms that combine instruments and proprietary reagents, speed to commercialization for next generation sequencing and liquid biopsy applications, and geographic reach into high-growth emerging markets. Established players are defending share through M&A and strategic co-development agreements, while focused innovators such as Tracer Biotechnologies are carving out positions in high-value niches like minimal residual disease monitoring. Close to 90% of profiled companies offer next generation sequencing technologies, signaling intense competitive convergence around that platform.

Browse Full Report Description + Research Methodology + Table of Content + Infographics here:
https://www.rootsanalysis.com/reports/molecular-diagnostics-market.html

Contact Details
Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com
Website: https://www.rootsanalysis.com

About Roots Analysis
Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

This release was published on openPR.